Denali Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report covers the annual meeting of stockholders held by Denali Therapeutics Inc. on May 31, 2024. The report details the voting results for three proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
As of the record date (April 5, 2024), 142,539,529 shares were outstanding. 118,315,456 shares (83.0%) were represented at the meeting. The voting results were as follows:
- Proposal 1 (Election of Directors): All three Class I nominees were elected to serve until the 2027 annual meeting.
- Jay Flatley: 108,094,205 For; 2,149,100 Withheld.
- Mac Tessier-Lavigne, Ph.D.: 82,215,374 For; 28,027,931 Withheld.
- Nancy A. Thornberry: 108,270,582 For; 1,972,723 Withheld.
- Proposal 2 (Ratification of Auditors): The appointment of Ernst & Young LLP for the fiscal year ending December 31, 2024, was ratified.
- For: 117,978,800; Against: 297,039; Abstain: 39,617.
- Proposal 3 (Executive Compensation): The advisory vote to approve executive compensation was approved.
- For: 101,612,037; Against: 8,587,858; Abstain: 43,410.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of shareholder voting results.
Key Facts for Investor Verification
- Verify the significant number of votes withheld for director nominee Mac Tessier-Lavigne, Ph.D. (28,027,931 votes) compared to the other nominees.
- Confirm the total number of shares represented at the meeting (83.0% of outstanding shares).
- Note that the ratification of Ernst & Young LLP covers the fiscal year ending December 31, 2024.
- Review the "Against" votes for the executive compensation proposal (8,587,858) to assess shareholder sentiment on pay practices.